FDA Grants Fast Track Designation to DKN-01 for Gastric and Gastroesophageal Junction Cancer

Article

The designation was granted to DKN-01 for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors express high levels of DKK1.

The FDA granted fast track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors express high Dickkopf-1 protein (DKK1), following disease progression on or after prior fluoropyrimidine- and platinum- containing chemotherapy and if appropriate, HER2/neu-targeted therapy, according to Leap Therapeutics, the developer of the agent.

Notably, the first patient was dosed in a combination study of DKN-01 plus tislelizumab (BGB-A317) in patients with gastric or gastroesophageal junction cancer in September 2020.

"We are pleased with the FDA's decision to grant fast track designation for the development of DKN-01 to treat patients with gastric and gastroesophageal junction cancer whose tumors express high levels of DKK1," Douglas E. Onsi, president and chief executive officer of Leap, said in a press release. "The designation highlights the existing unmet medical need for new and effective treatments for this patient population. We believe that DKN-01 shows promise as a novel treatment option for biomarker-selected patients with these cancers, and this designation provides us with earlier and more frequent opportunities to interact with the FDA during the development of DKN-01."

DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of DKK1 protein, a modulator of Wnt/Beta-catenin signaling, which is a signaling pathway often involved in tumorigenesis and suppressing the immune system. Currently, DKN-01 is being evaluated in clinical trials for gastroesophageal, gynecologic, hepatobiliary, and prostate cancers.

DKN-01 has also previously received orphan drug designation for the treatment of gastric and gastroesophageal junction cancer from the FDA.

Reference:

Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer [news release]. Cambridge, Massachusetts. Published September 24, 2020. Accessed September 24, 2020. https://investors.leaptx.com/news-releases/news-release-details/leap-therapeutics-announces-fda-fast-track-designation-granted

Recent Videos
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Related Content